1. Home
  2. ALPS vs SPRO Comparison

ALPS vs SPRO Comparison

Compare ALPS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALPS Group Inc Ordinary Share

ALPS

ALPS Group Inc Ordinary Share

SELL

Current Price

$0.34

Market Cap

66.6M

Sector

N/A

ML Signal

SELL

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

73.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALPS
SPRO
Founded
2017
2013
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.6M
73.4M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
ALPS
SPRO
Price
$0.34
$1.17
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
47.7K
★ 826.9K
Earning Date
07-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.81
EPS
★ N/A
N/A
Revenue
N/A
★ $66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 39.24
52 Week Low
$0.23
$1.08
52 Week High
$1.72
$3.08

Technical Indicators

Market Signals
Indicator
ALPS
SPRO
Relative Strength Index (RSI) 37.08 45.45
Support Level $0.23 $1.10
Resistance Level $0.44 $1.28
Average True Range (ATR) 0.02 0.07
MACD -0.01 0.00
Stochastic Oscillator 22.10 16.67

Price Performance

Historical Comparison
ALPS
SPRO

About ALPS ALPS Group Inc Ordinary Share

ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: